Corrigendum: Safety and dose modification for patients receiving niraparib (Annals of Oncology (2018) DOI: 10.1093/annonc/mdy181)

Authors :: Berek, J
Matulonis, U
Peen, U
Ghatage, P
Mahner, S
Redondo, A
Lesoin, A
Colombo, N
Vergote, I
Rosengarten, O
Ledermann, J
Pineda, M
Ellard, S
Sehouli, J
Gonzalez-Martin, A
Berton-Rigaud, D
Madry, R
Reinthaller, A
Hazard, S
Guo, W
Mirza, M
Berek J. S.
Matulonis U. A.
Peen U.
Ghatage P.
Mahner S.
Redondo A.
Lesoin A.
Colombo N.
Vergote I.
Rosengarten O.
Ledermann J.
Pineda M.
Ellard S.
Sehouli J.
Gonzalez-Martin A.
Berton-Rigaud D.
Madry R.
Reinthaller A.
Hazard S.
Guo W.
Mirza M. R.
Berek, J
Matulonis, U
Peen, U
Ghatage, P
Mahner, S
Redondo, A
Lesoin, A
Colombo, N
Vergote, I
Rosengarten, O
Ledermann, J
Pineda, M
Ellard, S
Sehouli, J
Gonzalez-Martin, A
Berton-Rigaud, D
Madry, R
Reinthaller, A
Hazard, S
Guo, W
Mirza, M
Berek J. S.
Matulonis U. A.
Peen U.
Ghatage P.
Mahner S.
Redondo A.
Lesoin A.
Colombo N.
Vergote I.
Rosengarten O.
Ledermann J.
Pineda M.
Ellard S.
Sehouli J.
Gonzalez-Martin A.
Berton-Rigaud D.
Madry R.
Reinthaller A.
Hazard S.
Guo W.
Mirza M. R.
Publication Year :: 2019
Abstract: The statement ". . .patients under 300 mg. . ." has been changed to ". . .patients at 300 mg. . ." (p3; line 29) to prevent misinterpretation on rates of thrombocytopenia in patients who remained at the 300 mg dose. Table S3 has also been revised to clearly show the relevant information to support the statement on p3. This also provides further information about rates of hematologic toxicities by dose level to better inform readers.

Tools